Last updated on November 2019

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients


Brief description of study

This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, pre-treatment, treatment & follow-up, and survival. After tisagenlecleucel infusion, efficacy will be assessed at Day 29, then every 3 months for the first year, every 6 months for the second year, then yearly until the end of the study. Safety will be assessed throughout the study. The study is expected to end in approximately 8 years after first patient first treatment (FPFT). A post-study long term follow-up for lentiviral vector safety will continue under a separate protocol per health authority guidelines.

Clinical Study Identifier: NCT03876769

Find a site near you

Start Over

Novartis Investigative Site

Paris Cedex 19, France
5.69miles
  Connect »